Disability-Adjusted Life Years Analysis: Implications for Stroke Research
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Stroke is a prototype disorder that disables as well as kills people. The disability-adjusted life years (DALY) metric developed by the World Health Organization to measure the global burden of disease integrates healthy life years lost due to both premature mortality and living with disability. Accordingly, it is well suited to stroke research. The DALY has previously been applied only to large but relatively crude population-level data analyses, but now it is possible to calculate the DALY lost in individual stroke patients. Measuring each patient’s stroke outcome with DALY lost has expanded its application to the analysis of treatment effect in acute stroke trials, delineating the poststroke complication impact, the differential weighting of discrete vascular events, and estimating a more refined stroke burden in a specific population. The DALY metric has several advantages over conventional stroke outcome measures: 1) Since the DALY measures the burden of diverse health conditions with a common metric of life years lost, stroke burden and benefits of stroke interventions can be directly compared to other health conditions and their treatments. 2)Quantifying stroke burden or interventional benefits as the life years lost or gained makes the DALY metric more intuitively accessible for public and health system planners. 3) As a continuous, equal-interval scale, the DALY analysis might be statistically more powerful than either binary or ordinal rank outcome analyses in detecting the treatment effects of clinical trials. 4) While currently employed stroke outcome measures take one-time snapshots of disability or mortality and implicitly indicate long-term health impact, the DALY explicitly indicates the burdens of living with disability for an individual’s remaining life.
Abstract
Stroke is a prototype disorder that disables as well as kills people. The disability-adjusted life years (DALY) metric developed by the World Health Organization to measure the global burden of disease integrates healthy life years lost due to both premature mortality and living with disability. Accordingly, it is well suited to stroke research. The DALY has previously been applied only to large but relatively crude population-level data analyses, but now it is possible to calculate the DALY lost in individual stroke patients. Measuring each patient’s stroke outcome with DALY lost has expanded its application to the analysis of treatment effect in acute stroke trials, delineating the poststroke complication impact, the differential weighting of discrete vascular events, and estimating a more refined stroke burden in a specific population. The DALY metric has several advantages over conventional stroke outcome measures: 1) Since the DALY measures the burden of diverse health conditions with a common metric of life years lost, stroke burden and benefits of stroke interventions can be directly compared to other health conditions and their treatments. 2)Quantifying stroke burden or interventional benefits as the life years lost or gained makes the DALY metric more intuitively accessible for public and health system planners. 3) As a continuous, equal-interval scale, the DALY analysis might be statistically more powerful than either binary or ordinal rank outcome analyses in detecting the treatment effects of clinical trials. 4) While currently employed stroke outcome measures take one-time snapshots of disability or mortality and implicitly indicate long-term health impact, the DALY explicitly indicates the burdens of living with disability for an individual’s remaining life.
참고문헌 (24)
- Murray CJL, "Rethinking DALYs in: The Global Burden of Disease. Vol 1 of Global Burden of Disease and Injury Series", pp.1~98 (1996), Harvard School of Public Health
- "The Global Burden of Disease: 2004 Update"[URL]
- "Global Burden of Disease 2004 Update: Disability Weights for Diseases and Conditions"[URL]
- Ezzati M, "Comparative Risk Assessment Collaborating Group. Estimates of global and regional potential health gains from reducing multiple major risk factors", Lancet, 352, pp.271~280 (2003)
- Moodie ML, "Trial application of a Model of Resource Utilization, Costs, and Outcomes for Stroke (MORUCOS) to assist priority setting in stroke", Stroke, 35, pp.1041~1046 (2004)
- Hong KS, "Quantifying the value of stroke disability outcomes: WHO global burden of disease project disability weights for each level of the modified Rankin Scale", Stroke, 40, pp.3828~3833 (2009)
- Hong KS, "Years of disability-adjusted life gained as a result of thrombolytic therapy for acute ischemic stroke", Stroke, 41, pp.471~477 (2010)
- Hong KS, "Years of Optimum Health Lost Due to Complications After Acute Ischemic Stroke Disability-Adjusted Life-Years Analysis", STROKE, 41, pp.1758~1765, LIPPINCOTT WILLIAMS & WILKINS
- Eriksson M, "Functional outcome 3 months after stroke predicts long-term survival", Cerebrovasc Dis, 25, pp.423~429 (2008)
- Slot KB, "Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies", BMJ, 336, pp.376~379 (2008)
- Hacke W, "Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators", Lancet, 352, pp.1245~1251 (1998)
- Ogawa A, "Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan", Stroke, 38, pp.2633~2639 (2007)
- Bae HJ, "In-hospital medical complications and long-term mortality after ischemic stroke", STROKE, 36, pp.2441~2445, LIPPINCOTT WILLIAMS & WILKINS
- Hong KS, "Impact of neurological and medical complications on 3-month outcomes in acute ischaemic stroke", Eur J Neurol, 15, pp.1324~1331 (2008)
- Sulter G, "Admitting acute ischemic stroke patients to a stroke care monitoring unit versus a conventional stroke unit: a randomized pilot study", Stroke, 34, pp.101~104 (2003)
- Hinchey JA, "Formal dysphagia screening protocols prevent pneumonia", Stroke, 36, pp.1972~1976 (2005)
- Korea Centers for Disease Control and Prevention, "Construction of National Surveillance System for Cardiovascular & Cerebrovascular Diseases", ~ (2006)
- Brott TG, "Stenting versus endarterectomy for treatment of carotid-artery stenosis", N Engl J Med, 363, pp.11~23 (2010)
- Peeters A, "A cardiovascular life history. A life course analysis of the original Framingham Heart Study cohort", Eur Heart J, 23, pp.458~466 (2002)
- Hong KS, "Weighting components of composite end points in clinical trials: an approach using disability-adjusted life-years", Stroke, 42, pp.1722~1729 (2011)
- Maddox TM, "Angina at 1 year after myocardial infarction: prevalence and associated findings", Arch Intern Med, 168, pp.1310~1316 (2008)
- Lloyd-Jones D, "Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee", Circulation, 119, pp.480~486 (2009)
- Johnston SC, "Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling", Lancet Neurol, 8, pp.345~354 (2009)
- 홍근식, "Burden of Ischemic Stroke in Korea: Analysis of Disability-Adjusted Life Years Lost", Journal of Clinical Neurology, 7(2), pp.77~84 (2011), 대한신경과학회